Altmetric

Focal laser ablation as clinical treatment of prostate cancer: Report from a Delphi consensus project

File Description SizeFormat 
Luijtelaar2019_Article_FocalLaserAblationAsClinicalTr.pdfPublished version672.77 kBAdobe PDFView/Open
Title: Focal laser ablation as clinical treatment of prostate cancer: Report from a Delphi consensus project
Authors: Van Luijtelaar, A
Greenwood, BM
Ahmed, HU
Barqawi, AB
Barret, E
Bomers, JGR
Brausi, MA
Choyke, PL
Cooperberg, MR
Eggener, S
Feller, JF
Frauscher, F
George, AK
Hindley, RG
Jenniskens, SFM
Klotz, L
Kovacs, G
Lindner, U
Loeb, S
Margolis, DJ
Marks, LS
May, S
Mcclure, TD
Montironi, R
Nour, SG
Oto, A
Polascik, TJ
Rastinehad, AR
De Reyke, TM
Reijnen, JS
De la Rosette, JJMCH
Sedelaar, JPM
Sperling, DS
Walser, EM
Ward, JF
Villers, A
Ghai, S
Fütterer, JJ
Item Type: Journal Article
Abstract: PURPOSE: To define the role of focal laser ablation (FLA) as clinical treatment of prostate cancer (PCa) using the Delphi consensus method. METHODS: A panel of international experts in the field of focal therapy (FT) in PCa conducted a collaborative consensus project using the Delphi method. Experts were invited to online questionnaires focusing on patient selection and treatment of PCa with FLA during four subsequent rounds. After each round, outcomes were displayed, and questionnaires were modified based on the comments provided by panelists. Results were finalized and discussed during face-to-face meetings. RESULTS: Thirty-seven experts agreed to participate, and consensus was achieved on 39/43 topics. Clinically significant PCa (csPCa) was defined as any volume Grade Group 2 [Gleason score (GS) 3+4]. Focal therapy was specified as treatment of all csPCa and can be considered primary treatment as an alternative to radical treatment in carefully selected patients. In patients with intermediate-risk PCa (GS 3+4) as well as patients with MRI-visible and biopsy-confirmed local recurrence, FLA is optimal for targeted ablation of a specific magnetic resonance imaging (MRI)-visible focus. However, FLA should not be applied to candidates for active surveillance and close follow-up is required. Suitability for FLA is based on tumor volume, location to vital structures, GS, MRI-visibility, and biopsy confirmation. CONCLUSION: Focal laser ablation is a promising technique for treatment of clinically localized PCa and should ideally be performed within approved clinical trials. So far, only few studies have reported on FLA and further validation with longer follow-up is mandatory before widespread clinical implementation is justified.
Issue Date: 22-Jan-2019
Date of Acceptance: 10-Jan-2019
URI: http://hdl.handle.net/10044/1/67097
DOI: https://dx.doi.org/10.1007/s00345-019-02636-7
ISSN: 0724-4983
Publisher: Springer Verlag
Journal / Book Title: World Journal of Urology
Copyright Statement: © 2019 The Author(s). Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Sponsor/Funder: Wellcome Trust
Funder's Grant Number: 204998/Z/16/Z
Keywords: Consensus
Delphi
Focal laser ablation
Laser focal therapy
Prostate cancer
1103 Clinical Sciences
Urology & Nephrology
Publication Status: Published online
Conference Place: Germany
Online Publication Date: 2019-01-22
Appears in Collections:Division of Surgery
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx